Table 1.
Patients’ characteristics.
| n = 27 (%) | |||
| Treatment group | |||
| RT: | 13 (48) | ||
| RT + erlotinib: | 14 (52) | ||
| Gender | |||
| Male: | 21 (78) | ||
| Female: | 6 (22) | ||
| Smoking history | |||
| Current: | 7 (26) | ||
| Former: | 20 (74) | ||
| Stage | |||
| III: | 7 (26) | ||
| IV: | 20 (74) | ||
| Histology | |||
| Adenocarcinoma: | 15 (56) | ||
| Squamous cell carcinoma: | 9 (33) | ||
| NOS: | 3 (11) | ||
| COPD | |||
| Positive: | 10 (37) | ||
| Negative: | 17 (63) | ||
| Available PET/CT Scans | |||
| Pre-therapy: | RT | 10 (37) | |
| RT + erlotinib | 9 (33) | ||
| Mid-therapy: | RT | 13 (48) | |
| RT + erlotinib | 12 (44) | ||
| Post-therapy: | RT | 5 (18) | |
| RT + erlotinib | 8 (30) | ||
Abbreviations: RT: Radiotherapy, NOS: Not otherwise specified, COPD: Chronic obstructive pulmonary disease.